Presented positive 72-week data from the ORIGIN Phase 2b trial of atacicept in IgAN, showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment.

Expanded management team with key appointments, including Robert M. Brenner, M.D., as Chief Medical Officer and William D. Turner as Chief Development Officer.

Actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN.

Completed $287.5 million financing in February, strengthening the Company’s balance sheet with $403.7 million in cash and equivalents as of March 31, 2024, extending the Company’s expected cash runway through potential approval and commercial launch.